TLR7 AGONIST CRYSTALLINE FORM A, PREPARATION METHOD AND USE THEREOF

The present invention relates to crystalline form A of a TLR7 agonist 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)-benzyl)-5H-pyrrolo[3,2-d] pyrimidin-4-amine (formula I), a method for preparing the crystalline form A, and the use thereof. La presente invencion se refiere a una forma cristalina A de un ago...

Full description

Saved in:
Bibliographic Details
Main Authors Zheng WANG, Yilong ZHOU, Fei SUN, Rui ZHAO, Zhaozhong DING, Ling YANG, Yinghu HU
Format Patent
LanguageEnglish
Spanish
Published 11.12.2018
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to crystalline form A of a TLR7 agonist 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)-benzyl)-5H-pyrrolo[3,2-d] pyrimidin-4-amine (formula I), a method for preparing the crystalline form A, and the use thereof. La presente invencion se refiere a una forma cristalina A de un agonista de TLR7 2-butoxi-7-(4-(pirrolidin-1-ilmetil)bencil)-5H-pi rrolo[3,2-d]pirimidin-4-amina (formula I), un método para preparar la forma cristalina A y su uso.
Bibliography:Application Number: MX20180009501